ANGPTL3 overcomes sorafenib resistance via suppression of SNAI1 and CPT1A in liver cancer
Liver cancer, encompassing hepatocellular carcinoma (HCC) and hepatoblastoma, the latter of which primarily occurs in early childhood, is the most common malignant tumor arising from liver and is responsible for a significant number of cancer-related deaths worldwide. Targeted drugs have been used f...
Saved in:
Main Authors: | Yang-Hsiang Lin, Cheng-Yi Chen, Hsiang-Cheng Chi, Meng-Han Wu, Ming-Wei Lai, Chau-Ting Yeh |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523324003760 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis
by: Yirui Zhai, et al.
Published: (2025-03-01) -
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01) -
HTR1D regulates the PI3K/Akt signaling pathway to impact hepatocellular carcinoma development and resistance to sorafenib
by: Yingai Zhang, et al.
Published: (2025-01-01) -
Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation
by: Chunxiao Li, et al.
Published: (2025-01-01) -
Single-cell transcriptomic profiling of heart reveals ANGPTL4 linking fibroblasts and angiogenesis in heart failure with preserved ejection fraction
by: Guoxing Li, et al.
Published: (2025-02-01)